No source found states or supports that Alzheimer's will be eradicated within five years. Not one.

The two drugs the post names are the strongest real evidence in the field, and both slow decline modestly rather than stopping or reversing disease. In CLARITY AD, lecanemab patients worsened by 1.21 points on CDR-SB versus 1.66 points on placebo over 18 months, a 27 percent relative slowing of decline. Note the direction: both groups got worse. For donanemab, Lilly reported 35 percent slowing of decline on the iADRS in the less advanced subgroup and 22 percent in the overall trial population over 18 months. The NIA describes these as slowing rates of cognitive and functional decline in people with early symptoms, not halting or curing.

Both drugs are approved only for mild cognitive impairment or mild dementia stage with confirmed amyloid pathology. Neither is indicated for moderate or advanced disease, and neither prevents the disease.

The FDA link the post itself cites is a safety communication, not a breakthrough announcement. In August 2025 the FDA recommended an additional, earlier MRI before the third lecanemab infusion to catch amyloid-related imaging abnormalities with edema (ARIA-E), brain swelling or fluid buildup that the FDA notes can be serious and life-threatening. In CLARITY AD, ARIA-E occurred in roughly 12.6 percent of lecanemab patients and ARIA-H (hemorrhage) in roughly 17.3 percent.

On vaccines: the claim that several have entered human trials is true. The post's own PubMed citation, ABvac40, is described as an investigational active immunotherapy targeting Aβ40 in a randomised, double-blind, placebo-controlled Phase 2 study. Other programs are earlier still. The UNM tau vaccine was expected to begin enrolling in early 2026 for a 12-month study. Alzamend Neuro's amyloid vaccine is a 30-person Phase 1-2 trial with results expected in 2028. GV1001 is in Phase 3 in South Korea, also expected to finish in 2028. A trial finishing in 2028 cannot produce an approved, globally deployed preventive vaccine that eradicates a disease by 2031.

On the trajectory of the disease itself: the leading global forecast projects adults aged 40 and over living with dementia will nearly triple from about 57 million in 2019 to about 153 million in 2050, driven by population growth and ageing.

The most optimistic institutional forecast located, from USC's Alzheimer's Therapeutic Research Institute, predicts that within the next ten years screening and preventive care could become routine. That is prevention and early detection within a decade, not eradication within five years. A UCSF researcher's framing was that in the next five or ten years a combination of therapies might halt, reverse or prevent onset, which is a conditional research aspiration, not a forecast of elimination.